Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 458 of 6351
-
New eye drug aims to block two causes of vision loss at once
Disease control Not yet recruitingOculgen has begun a study of an investigational drug called OCUL101 as a possible treatment for neovascular AMD. An investigational drug is one that has not been approved by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States (US), the Europea…
Phase 2/3 • Sponsor: Shenzhen Oculgen Biomedical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug azenosertib takes on Chemo-Resistant ovarian cancer in phase 3 trial
Disease control Recruiting nowThis is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
Phase 3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for stomach cancer patients with abdominal spread
Disease control Recruiting nowIn this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug shows promise for tough liver cancer cases
Disease control Recruiting nowThis study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail of drugs hopes to tackle tough breast cancer
Disease control Recruiting nowThis study is a single-arm, multicenter, prospective phase II clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for advanced triple-negative breast cancer. A total of 34 pa…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy could free kids from lifelong blood transfusions
Disease control Recruiting nowBrief summary The goal of this clinical trial is to learn if APR-2020 is safe and can help treat Diamond-Blackfan Anemia (DBA) in adolescents and children. The main questions it aims to answer are: * Is APR-2020 safe and well tolerated? * Does APR-2020 modify or correct an unde…
Phase 1 • Sponsor: Apriligen, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo aims to keep prostate cancer in check with lower chemo dose
Disease control Recruiting nowThis is a single-arm, prospective, multicenter, interventional study, aimed at exploring the efficacy and safety of darolutamide + ADT combined with low-dose docetaxel in treating patients with mHSPC planning to recruit approximately 109 patients. The purpose of this study is to…
Phase 2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New electric pulse therapy could replace radiation boost for prostate cancer
Disease control Recruiting nowIn this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-risk prostate cancer receiving standard s…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to shrink MALT lymphoma with less radiation damage
Disease control Recruiting nowThis is a prospective, multicenter Phase 2 clinical trial named the MALT-RO study, evaluating ultra-low-dose radiation therapy followed by orelabrutinib as first-line treatment for adults with Stage I-II MALT lymphoma. The study aims to determine the efficacy and safety profile o…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can a diabetes drug rev up muscle power?
Disease control Recruiting nowThe purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2 diabetes. As the primary outcome, the investigators …
Phase 4 • Sponsor: University Medical Centre Ljubljana • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug aims to reverse wasting in cancer patients
Symptom relief Recruiting nowA study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back …
Phase 2/3 • Sponsor: CatalYm GmbH • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Smart drug delivers chemo directly to cancer cells in new trial
Disease control Recruiting nowThis is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer. CKD-703 is composed of a c-Met-targeting monoc…
Phase 1/2 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for kidney transplant patients: extended drug trial targets rejection
Disease control By invitation onlyIn this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and then developed antibody-mediated rejection (AMR) or microvascular inflammation (MVI). AMR happens when the body's immune system creates donor-specific an…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 10, 2026 08:00 UTC
-
New imaging technique could help surgeons spot hidden parathyroid tumors
Diagnosis Recruiting nowBackground: People have 4 parathyroid glands near the thyroid gland in the neck. Surgery is needed to remove a parathyroid gland that is too large or has a tumor. These glands can be in different places, so doctors use an imaging scan with contrast dye to help find them before s…
Phase 2/3 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Can stem cells heal burn scars? new trial aims to find out
Disease control Recruiting nowThe present project serves to test whether stem cell therapy offers a new treatment option for the scars of burn survivors. In Denmark, 12.000 people seek medical assistance every year for burn injuries leaving thousands of people with the devastating condition of hypertrophic sc…
Phase 1/2 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Mindfulness via screen: a new hope for Burned-Out healthcare heroes?
Symptom relief OngoingHealthcare professionals may experience high levels of work-related stress and burnout. This study will examine whether an 8-week online Mindfulness-Based Stress Reduction (MBSR) program improves recovery from stress and other mental health outcomes in healthcare professionals wh…
Sponsor: Vilnius University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could delaying radiation be just as good for advanced nasopharyngeal cancer?
Disease control Recruiting nowThis phase III randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus salvage locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma. The study aims to evaluate whether salvage locoregional radiotherapy is non-inferior to immedi…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Balloon vs stent: new hope for heart patients with multiple blockages?
Disease control Not yet recruitingThis study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm…
Sponsor: Genoss Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Revolutionary CAR-T shot? new therapy builds cancer fighters inside you
Disease control Not yet recruitingThis study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects. DIT101 is an investigational in vivo CAR-T cell therap…
Phase 1 • Sponsor: Tcelltech Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Can radiotherapy and poop pills outsmart liver cancer resistance?
Disease control Recruiting nowThis is an open-label, multicenter, randomized controlled Phase II trial. Patients with advanced hepatocellular carcinoma (HCC) who developed secondary resistance to first-line targeted-immunotherapy were randomly assigned to receive either the original first-line targeted-immuno…
Phase 2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC